Table 5.
Sensitivity analysis of endpoints of interests.
| Endpoints (references) | No. of patients | No. of trials | NOSE | CL | OR or WMD (95%CI) | P-value | I2 (%) | P value for heterogeneity |
|---|---|---|---|---|---|---|---|---|
| LYMPH NODE HARVEST | ||||||||
| All included trails (4, 10, 11, 16, 26, 29, 30) | 727 | 7 | 295 | 432 | −0.97 (−1.97 to 0.03) | 0.06 | 0 | 0.76 |
| BMI ≤ 30 (kg/m2) (4, 11, 16, 26, 29, 30) | 687 | 6 | 275 | 412 | −0.87 (−1.89 to 0.16) | 0.10 | 0 | 0.77 |
| Sample number >30 (11, 16, 26, 29) | 569 | 4 | 239 | 330 | −0.59 (−1.99 to 0.80) | 0.41 | 0 | 0.64 |
| Non-RCT (NOS ≥ 6) (4, 10, 11, 16, 26, 29) | 679 | 6 | 279 | 400 | −0.71 (−1.98 to 0.56) | 0.27 | 0 | 0.71 |
| Prospective trials (16, 29, 30) | 232 | 3 | 108 | 124 | −1.11 (−2.59 to 0.38) | 0.14 | 0 | 0.53 |
| TOTAL PERIOPERATIVE COMPLICATIONS | ||||||||
| All included trails (4, 5, 9–11, 16, 24–29) | 1,317 | 12 | 609 | 708 | 0.56 (0.41 to 0.75) | <0.001 | 15 | 0.30 |
| BMI ≤ 30 (kg/m2) (4, 5, 11, 16, 24, 26, 27, 29) | 1,001 | 8 | 440 | 561 | 0.50 (0.34 to 0.74) | <0.001 | 0 | 0.52 |
| Sample number > 30 (5, 11, 16, 25, 26, 29) | 1,065 | 6 | 499 | 566 | 0.57 (0.41 to 0.79) | <0.001 | 0 | 0.59 |
| Non-RCT (NOS ≥ 6) (4, 5, 9–11, 16, 25, 26, 28, 29) | 1,231 | 10 | 566 | 665 | 0.57 (0.42 to 0.78) | <0.001 | 11 | 0.34 |
| Prospective trials (5, 9, 16, 24, 29) | 526 | 5 | 267 | 259 | 0.58 (0.36 to 0.93) | 0.03 | 0 | 0.41 |
| ANASTOMOTIC LEAKAGE | ||||||||
| All included trails (5, 9, 11, 26, 27, 29) | 819 | 6 | 383 | 436 | 0.71 (0.36 to 1.38) | 0.31 | 0 | 0.96 |
| BMI ≤ 30 (kg/m2) (5, 11, 26, 27, 29) | 793 | 5 | 366 | 427 | 0.68 (0.34 to 1.34) | 0.26 | 0 | 0.95 |
| Sample number > 30 (5, 11, 26, 29) | 747 | 4 | 343 | 404 | 0.70 (0.35 to 1.42) | 0.33 | 0 | 0.92 |
| Non-RCT (NOS ≥ 6) (5, 9, 11, 26, 29) | 773 | 5 | 360 | 413 | 0.73 (0.37 to 1.46) | 0.38 | 0 | 0.94 |
| Prospective trials (5, 29) | 392 | 2 | 196 | 196 | 0.75 (0.31 to 1.78) | 0.51 | 0 | 0.60 |
| SURGICAL SITE INFECTION | ||||||||
| All included trails (4, 5, 10, 12, 26, 29, 30) | 808 | 7 | 369 | 439 | 0.15 (0.05 to 0.42) | <0.001 | 0 | 0.99 |
| BMI ≤ 30 (kg/m2) (4, 5, 12, 26, 29, 30) | 768 | 6 | 349 | 419 | 0.14 (0.04 to 0.42) | <0.001 | 0 | 0.99 |
| Sample number > 30 (5, 12, 26, 29) | 650 | 4 | 313 | 337 | 0.12 (0.03 to 0.45) | 0.002 | 0 | 1.00 |
| Non-RCT (NOS ≥ 6) (4, 5, 10, 26, 29) | 690 | 5 | 318 | 372 | 0.14 (0.04 to 0.47) | 0.001 | 0 | 0.99 |
| Prospective trials (5, 12, 29, 30) | 510 | 4 | 247 | 263 | 0.14 (0.04 to 0.53) | 0.004 | 0 | 0.93 |
| OPERATION TIME | ||||||||
| All included trails (4, 5, 9–12, 16, 26–30) | 1,175 | 12 | 518 | 657 | 17.34 (6.14 to 28.54) | 0.002 | 81 | <0.001 |
| BMI ≤ 30 (kg/m2) (4, 5, 11, 12, 16, 26, 27, 29, 30) | 1,079 | 9 | 471 | 608 | 13.17 (1.86 to 24.47) | 0.02 | 80 | <0.001 |
| Sample number > 30 (5, 11, 12, 16, 26, 29) | 915 | 6 | 412 | 503 | 11.08 (0.46 to 21.70) | 0.04 | 72 | 0.003 |
| Non-RCT (NOS ≥ 6) (4, 5, 9–11, 16, 26, 28, 29) | 1,011 | 9 | 444 | 567 | 14.84 (1.04 to 28.63) | 0.03 | 81 | <0.001 |
| Prospective trials (5, 9, 12, 16, 29, 30) | 604 | 6 | 298 | 306 | 17.36 (11.43 to 23.28) | <0.001 | 0 | 0.65 |
| HOSPITAL STAY | ||||||||
| All included trails (4, 5, 9–12, 16, 26–30) | 1,175 | 12 | 518 | 657 | −0.56 (−1.09 to −0.04) | 0.03 | 54 | 0.01 |
| BMI ≤ 30 (kg/m2) (4, 5, 11, 12, 16, 26, 27, 29, 30) | 1,079 | 9 | 471 | 608 | −0.71 (−1.19 to −0.23) | 0.004 | 51 | 0.04 |
| Sample number > 30 (5, 11, 12, 16, 26, 29) | 915 | 6 | 412 | 503 | −0.84 (−1.16 to −0.53) | <0.001 | 43 | 0.12 |
| Non-RCT (NOS ≥ 6) (4, 5, 9–11, 16, 26, 28, 29) | 1,011 | 9 | 444 | 567 | −0.88 (−1.21 to −0.56) | <0.001 | 41 | 0.09 |
| Prospective trials (5, 9, 12, 16, 29, 30) | 604 | 6 | 298 | 306 | −0.57 (−1.35 to 0.20) | 0.15 | 62 | 0.02 |
NOSE, natural orifice specimen extraction; CL, conventional laparoscopic surgery; OR, odds ratio; WMD, weighted mean difference; 95%CI; 95% confidence interval; BMI, body mass index.